An oral capsule that vibrates as it moves through the digestive tract has shown notable promise as a non-pharmacological treatment for constipation, according to new research presented today at Digestive Disease Week (DDW). In the pilot study, the vibrating capsule was found to nearly double the weekly bowel movements of patients suffering from chronic idiopathic constipation (CIC) and constipation predominant irritable bowel syndrome (C-IBS).
‘Despite the widespread use of medication to treat constipation, nearly 50 percent of patients are unsatisfied with the treatment either because of side effects, safety concerns about long-term use, or the fact that it simply doesn
Astrocytomas are the most common malignant brain tumours. While most patients
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:40:372020-08-26 14:40:47Gene mutation defines brain tumours that benefit from aggressive surgery
Inhibiting enzymes that cause changes in gene expression could decrease chemotherapy resistance in ovarian cancer patients, researchers at Georgia State University and the University of Georgia say.
Dr. Susanna Greer, associate professor of biology, and research partners at the University of Georgia have identified two enzymes that suppress proteins that are important for regulating cell survival and chemoresistance in ovarian cancer.
Ovarian cancer is one of the deadliest gynaecological cancers, with a 60 percent mortality rate and a five-year survival rate for less than 30 percent of women in the advanced stage of the disease. The high mortality rate is largely due to the development of resistance to chemotherapeutic drugs. Understanding the molecular and genetic mechanisms that drive the development of acquired chemoresistance can help improve therapeutic agents for ovarian cancer treatment.
‘Ovarian cancer is usually treated by surgery followed by chemotherapy,’ Greer said, ‘but because it’s typically found fairly late, ovarian cancer is often refractory to chemotherapy. You have tumours that initially respond to chemotherapy and then don’t. Ovarian cancer is the 8th most commonly diagnosed cancer in U.S. women, but due to its late diagnosis, causes more deaths than any other cancer of the female reproductive system.’
In a previous study, Greer found the expression of the protein RGS10, which regulates ovarian cancer cell growth and survival, is suppressed in ovarian cancer cells that are chemoresistant. The suppression was caused by two important mechanisms that silence genes and contribute to the progression of many cancers – DNA methylation, a biochemical process in which a methyl group is added to specific building blocks of DNA, and histone deacetylation, a process in which enzymes remove functional groups of atoms from proteins associated with DNA.
In their study, the researchers investigate the silencing of RGS10 expression in ovarian cancer cells by epigenetics, which is heritable changes in genes and gene expression that are not caused by changes in the DNA sequence, but rather by reversible and self-perpetuating mechanisms of DNA programming.
They identified two epigenetic regulators, HDAC1, a histone deacetylase, and DNMT1, a DNA methyl transferase. Decreasing the expression of HDAC1 and DNMT1 and blocking their activity significantly increased RGS10 expression and cell death. This also decreased the binding of HDAC1 to RGS10 in chemoresistant cells.
The research suggests that inhibiting HDAC1 and DNMT1 could be a novel therapeutic approach to overcoming chemoresistance in ovarian cancer.
EurekAlert
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:40:372020-08-26 14:40:46Researchers find way to decrease chemoresistance in ovarian cancer
Pregnant women with obstructive sleep apnea are more than five times as likely to die in the hospital than those without the sleep disorder, a comprehensive national study by University of South Florida researchers found.
Among delivery-related hospital discharges, sleep apnea was also associated with an increase in severe medical conditions that are top causes of maternal death, including pre-eclampsia, eclampsia, an enlarged heart and pulmonary blood clots.
Dr. Judette Louis, assistant professor of obstetrics and gynaecology at the USF Health Morsani College of Medicine, led the large-scale national study appearing in the journal SLEEP. She specialises in maternal-foetal medicine, working out of Tampa General Hospital.
Sleep apnea causes repeated awakenings and pauses in breathing during the night. Previous smaller studies have found that the condition increases the risk for poor pregnancy outcomes, including pre-eclampsia (high blood pressure in pregnancy associated with loss of protein in the urine), restricted growth of the foetus, preterm delivery and gestational diabetes. Obesity appears to contribute to the adverse effects.
However, the USF study provided the first large-scale U.S. analysis of the association between sleep apnea and maternal deaths.
‘The astounding association with maternal death was surprising,’ said lead author Judette Louis, MD, MPH, assistant professor of obstetrics and gynaecology at the USF Health Morsani College of Medicine who works out of Tampa General Hospital. ‘I did not expect to find such a difference in mortality between pregnant women who had sleep apnea and those who did not, especially when we controlled for obesity and other complicating factors.
While more study is needed, the increased likelihood of death for those with sleep apnea may be explained in part by the physiological demands of pregnancy, she said. ‘Underlying damage or chronic disease caused by sleep apnea may be exacerbated by the stresses of pregnancy.’
Maternal death rates have increased slightly in recent years, and obesity is one suspected reason.
‘Our study indicates that sleep apnea may also play a role, whether a woman is obese or not,’ said Dr. Louis, who holds a joint appointment in the USF College of Public Health
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:40:372020-08-26 14:40:46Study shows link between sleep apnea and hospital maternal deaths
New research from Finland suggests in the not-too-distant future we may be making rapid, early diagnoses of prostate cancer using a non-invasive electronic nose that sniffs a urine sample.
Researchers from the University of Tampere describe how the ‘eNose’ successfully differentiated between prostate cancer and benign prostatic hyperplasia (BPH) by analysing the ‘smell print’ of the headspace of a urine sample (the air immediately above the urine).
The team says the results from the eNose are comparable to those obtained from prostate specific antigen (PSA) tests.
Prostate cancer is the second most common cancer in men and one of the leading causes of death from cancer. It is not easy to diagnose and make reliable prognoses about prostate cancer because it does not appear consistently in prostate tissue.
Currently, doctors rely on the digital rectal exam (DRE) and the PSA test to help decide if a biopsy is necessary. But these can be hit and miss, while biopsies are costly and uncomfortable, and carry the risk of infection. The other problem with current methods is that many diagnosed prostate cancers will not become life-threatening, and aggressive treatment risks reducing quality of life without extending it.
Odour sampling begins to show promise as a diagnostic for cancer
There have been experiments to test dogs’ ability to sniff out cancer, but scientists have noticed a lot of variation in their performance between and during studies.
About 20 or so years ago, researchers became interested in reports that dogs were detecting cancer in their owners, and since then there have been experiments to test dogs’ ability to sniff out cancer.
For example, in 2010, a scientific meeting of the American Urological Association learned how researchers in Paris had trained dogs to sniff out prostate cancer. They showed the dogs could detect certain prostate cancer cell-derived volatile organic compounds (VOCs) in urine.
However, as more research has been done using dogs, so scientists have noticed a lot of variation in their performance between and during studies, so their findings have limited application.
A more promising avenue is the growth of labs working on the electronic equivalent of sniffer dogs – artificial olfaction or electronic nose technology. For instance, in 2012 we were taken behind the scenes of an electronic nose lab at the California Institute of Technology, and learned how investigators in that lab foresee that one day we will be using smartphones to sniff out diseases.
Electronic noses or ‘eNoses’ that analyse complex mixtures of gas molecules are already used in food and agriculture quality control, and in military applications.
Exhaled air is a ‘problematic sampling material’
eNoses are already being investigated for medical use, including early detection of cancer from exhaled air, says lead investigator Dr. Niku Oksala, of the Department of Surgery in the School of Medicine at the University.
‘However, exhaled air is a problematic sample material since it requires good cooperation and technique from the patient and immediate analysis,’ notes Dr. Oksala, who is also of the Department of Vascular Surgery, Tampere University Hospital.
He points out that urine, on the other hand, is simple to obtain and easy to store, and more feasible for use in clinical practice. Plus, he says:
‘Preliminary data suggested that detection of urologic malignancies from urine headspace was possible. Our own preliminary results on prostate cancer cells encouraged us to launch this prospective clinical study.’
MNT
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:40:372020-08-26 14:40:46‘eNose’ that sniffs out prostate cancer shows promise
People who need multiple surgeries for congenital heart defects undergo procedures that are invasive and challenging partly due to an inability to quickly and safely secure devices inside the heart. Sutures take too much time to stitch and can stress fragile heart tissue, and available clinical adhesives are sub-par. The creation of a safe and effective adhesive that can be used internally in the body would help these patients, but researchers trying to develop a glue like this have faced hurdles such as ensuring that it is non-toxic and capable of repelling fluids. Now, a study published by Harvard Medical School offers a potential breakthrough.
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:40:372020-08-26 14:40:45New surgical glue could provide alternative for heart procedures
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:40:372020-08-26 14:40:45Siemens wins major healthcare IT contract
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:40:372020-08-26 14:40:45Maquet and Pulsion announce cooperation in advanced monitoring
The ZNA hospital network of Antwerp, Belgium, is extending its existing Agfa HealthCare ICIS imaging platform beyond radiology.. With the deployment, all other image-producing departments of the hospital group will be integrated, whether they produce DICOM or non-DICOM images. In addition, patient images from other facilities can be quickly and easily imported as well. The ICIS VIEW zero footprint image viewer will be implemented for internal and external image distribution, for all types of medical images. With nine sites in the Antwerp area, ZNA is not only among Belgium
https://interhospi.com/wp-content/uploads/sites/3/2020/06/logo-footer.png442003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-08-26 14:40:372020-08-26 14:40:44ZNA hospital group in Belgium extends Agfa HealthCare?s ICIS to integrate all medical images onto single cloud-based platform
We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.
Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.
Essential Website Cookies
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.
We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.
We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.
.
Google Analytics Cookies
These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.
If you do not want us to track your visit to our site, you can disable this in your browser here:
.
Other external services
We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page
Google Webfont Settings:
Google Maps Settings:
Google reCaptcha settings:
Vimeo and Youtube videos embedding:
.
Privacy Beleid
U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.